TP53-mutated clones are well-documented for their resistance to chemotherapy, which predominantly relies on DNA damage-induced apoptosis, and they are recognized as early drivers in the pathogenesis of MDS and AML (27, 28). Here, TP53 is linked to acute myeloid leukemia.